Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_2
4
80%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

withdrawn120%
completed360%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
completedphase_2

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

NCT02289950
completedphase_2

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

NCT01218516
completedphase_2

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

NCT00318370
withdrawnphase_2

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

NCT01203618

Clinical Trials (5)

Showing 5 of 5 trials
NCT00849667Phase 3

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Terminated
NCT02289950Phase 2

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Completed
NCT01218516Phase 2

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Completed
NCT00318370Phase 2

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Completed
NCT01203618Phase 2

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5